PR 300
Alternative Names: PR-300Latest Information Update: 20 Jun 2023
Price :
$50 *
At a glance
- Originator Prometheus Biosciences
- Developer Merck & Co
- Class Anti-inflammatories; Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 16 Jun 2023 Prometheus Biosciences has been acquired and merged into Merck & Co
- 11 Apr 2023 Preclinical trials in Crohn's disease in USA (unspecified route) (Prometheus Biosciences pipeline, April 2023).
- 11 Apr 2023 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route) (Prometheus Biosciences pipeline, April 2023).